MétaCan
Menu
Back to cohort
Record W3136693186 · doi:10.1111/dom.14386

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial

2021· article· en· W3136693186 on OpenAlexaff
Clare Arnott, Jing‐Wei Li, Christopher P. Cannon, Dick de Zeeuw, Brendon L. Neuen, Hiddo J.L. Heerspink, David M. Charytan, Anubha Agarwal, Mark D. Huffman, Gemma A. Figtree, George L. Bakris, Tara I. Chang, Kent Y. Feng, Norman Rosenthal, Bernard Zinman, Meg Jardine, Vlado Perkovic, Bruce Neal, Kenneth W. Mahaffey

Bibliographic record

VenueDiabetes Obesity and Metabolism · 2021
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsLunenfeld-Tanenbaum Research InstituteUniversity of Toronto
FundersMitsubishi Tanabe Pharma Corporation
KeywordsCanagliflozinMedicineHazard ratioHeart failureInternal medicineEmpagliflozinProportional hazards modelRenal functionType 2 diabetesDiabetes mellitusKidney diseaseCardiologyConfidence intervalEndocrinology

Abstract

fetched live from OpenAlex

Abstract Heart failure is prevalent in those with type 2 diabetes and chronic kidney disease, and is associated with significant mortality and morbidity. In the CREDENCE trial, canagliflozin reduced the risk of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 31%. In the current analysis we sought to determine whether the effect of canagliflozin on HHF/CV death differed in subgroups defined by key baseline participant characteristics. Cox regression models were used to estimate hazard ratios and 95% confidence intervals. Canagliflozin was associated with a reduction in the relative risk of HHF/CV death regardless of age, sex, history of heart failure or CV disease, and the use of loop diuretics or glucagon‐like peptide‐1 receptor agonists (all p interaction > .114). The absolute benefit of canagliflozin was greater in those at highest baseline risk, such as those with CV disease (50 fewer events/1000 patients treated over 2.5 years vs. 20 fewer events in those without CV disease) or advanced kidney disease (estimated glomerular filtration rate [eGFR] 30–45 mL/min/1.73m 2 : 61 events prevented/1000 patients treated over 2.5 years vs. 23 events in eGFR 60–90 mL/min/1.73m 2 ). Canagliflozin consistently reduces the proportional risk of HHF/CV death across a broad range of subgroups with greater absolute benefits in those at highest baseline risk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.013
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.071

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0130.011
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.007
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.219
Teacher spread0.209 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations20
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueDiabetes Obesity and MetabolismSame topicDiabetes Treatment and ManagementFrench-language works237,207